Which ASX ETFs hold Halozyme Therapeutics Inc (HALO)?
As at Q3 2026, HALO is among the most widely held stocks across ASX-listed ETFs, appearing in approximately 5 ETFs. Its largest single position is approximately 3.76% in ROYL (Betashares Global Royalties ETF). General information only, not financial advice.
General information only, not financial advice. ETFLens does not hold an AFSL. Always read the relevant PDS and consider seeking advice from a licensed financial adviser.
All weights are approximate, drawn from each fund's published holdings as at Q3 2026, and change as funds rebalance.
| ETF | Fund | Category | Weight |
|---|---|---|---|
| ROYL | Betashares Global Royalties ETF | Thematic | approx. 3.76% |
| HLTH | VanEck Global Healthcare Leaders ETF | Thematic | approx. 3.06% |
| CURE | Global X S&P Biotech ETF | Thematic | approx. 1.38% |
| VISM | Vanguard MSCI International Small Companies Index ETF | Global Broad Market | approx. 0.09% |
| VTS | Vanguard US Total Market Shares Index ETF | US Shares | approx. 0.01% |
Want to see what any of these funds overlap with? Try the free ETF overlap checker, or browse the most widely held stocks.
Hold more than one of these? See your combined HALO exposure across all your ETFs with the Stock X-Ray.
HALO in ETFs: frequently asked questions
Which ASX ETFs hold HALO?
Halozyme Therapeutics Inc (HALO) is held by approximately 5 ASX-listed ETFs, including ROYL, HLTH, CURE, VISM, VTS. General information only.
Which ETF has the largest HALO weighting?
ROYL (Betashares Global Royalties ETF) has the largest HALO position at approximately 3.76% of the fund, as at Q3 2026. Past weightings are not a reliable indicator of future weightings.